This Article  • References  • Full text PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gary D. Tollefson, MD, PhD; Alvin H. Rampey, Jr, PhD; Janet H. Potvin, PhD; Michael A. Jenike, MD; A. John Rush, MD; Roberto A. Dominguez, MD; Lorrin M. Koran, MD; M. Katherine Shear, MD; Wayne Goodman, MD; Laura A. Genduso, PharmD

Arch Gen Psychiatry. 1994;51(7):559-567.

Abstract
Objectives
To determine the effectiveness of fluoxetine hydrochloride at fixed doses of 20 mg/d, 40 mg/d, and 60 mg/d in patients with obsessive-compulsive disorder (OCD) and to evaluate its safety.

Methods
Fixed-dose fluoxetine hydrochloride (20 mg/d, 40 mg/d, 60 mg/d) was compared with placebo in two randomized, double-blind, parallel, 13-week trials of identical design in 355 outpatients with OCD aged 15 to 70 years (DSM-III-R criteria; 1 year's duration or longer; depression secondary if present).

Results
Fluoxetine (all doses) was significantly (P±001) superior to placebo on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score (mean baseline-to-end—point decrease, 4.6,5.5, and 6.5 vs 0.9, respectively, studies pooled) and other efficacy measures (P±01). A trend suggesting greater efficacy at 60 mg/d was observed. Most patients (79.2%) completed the study. Eight adverse events were statistically significantly more frequent with fluoxetine and one, with placebo. For some events, incidence tended to increase with increasing dosage; however, few patients discontinued treatment for any single event.

Conclusion
Fluoxetine was associated with a statistically significant reduction in OCD severity, including time engaged in obsessional and/or compulsive behaviors. Adverse events infrequently led to study discontinuation.

Author Affiliations
From the Psychopharmacology Division, Eli Lilly and Company, Indianapolis, Ind (Drs Tollefson, Rampey, Potvin, and Genduso); the Departments of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Jenike), University of Texas Southwestern Medical School, Dallas (Dr Rush), University of Miami (Fla) School of Medicine, (Dr Dominguez); the Departments of Psychiatry and Behavioral Sciences, Stanford (Calif) University School of Medicine (Dr Koran); the Departments of Psychiatry, New York Hospital, Cornell University Medical College, Ithaca (Dr Shear); and Connecticut Mental Health Center, Yale University Medical School, New Haven (Dr Goodman). Dr Shear is currently with the University of Pittsburgh (Pa) Western Psychiatric Institute and Dr Goodman is currently with the University of Florida School of Medicine, Gainesville.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder
Foa et al.
Focus 2007;5:368-380.
ABSTRACT | FULL TEXT  

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
Baldwin et al.
J Psychopharmacol 2005;19:567-596.
ABSTRACT  

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder
Foa et al.
Am. J. Psychiatry 2005;162:151-161.
ABSTRACT | FULL TEXT  

A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder
Kaplan and Hollander
Focus 2004;2:454-461.
ABSTRACT | FULL TEXT  

Behavioral Versus Pharmacological Treatments of Obsessive Compulsive Disorder: A Meta-Analysis
Kobak et al.
Focus 2004;2:462-474.
ABSTRACT | FULL TEXT  

A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder
Kaplan and Hollander
Psychiatr. Serv. 2003;54:1111-1118.
ABSTRACT | FULL TEXT  

Efficacy of Sertraline in the Long-Term Treatment of Obsessive-Compulsive Disorder
Koran et al.
Am. J. Psychiatry 2002;159:88-95.
ABSTRACT | FULL TEXT  

Multicenter Double-blind Comparison of Sertraline and Desipramine for Concurrent Obsessive-Compulsive and Major Depressive Disorders
Hoehn-Saric et al.
Arch Gen Psychiatry 2000;57:76-82.
ABSTRACT | FULL TEXT  

Use of Factor-Analyzed Symptom Dimensions to Predict Outcome With Serotonin Reuptake Inhibitors and Placebo in the Treatment of Obsessive-Compulsive Disorder
Mataix-Cols et al.
Am. J. Psychiatry 1999;156:1409-1416.
ABSTRACT | FULL TEXT  

Axis I Comorbidity of Borderline Personality Disorder
Zanarini et al.
Am. J. Psychiatry 1998;155:1733-1739.
ABSTRACT | FULL TEXT  

Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial
March et al.
JAMA 1998;280:1752-1756.
ABSTRACT | FULL TEXT  

Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo
Michelson et al.
Am. J. Psychiatry 1998;155:1570-1577.
ABSTRACT | FULL TEXT  

Does Fluoxetine Augment the Inpatient Treatment of Anorexia Nervosa?
Attia et al.
Am. J. Psychiatry 1998;155:548-551.
ABSTRACT | FULL TEXT  

Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life
Goodnick and Goldstein
J Psychopharmacol 1998;12:S21-S54.
ABSTRACT  

Selective serotonin reuptake inhibitors in obsessive-compulsive disorder
DTB 1995;33:47-48.
ABSTRACT | FULL TEXT  

Efficacy and Tolerability of Serotonin Transport Inhibitors in Obsessive-compulsive Disorder: A Meta-analysis
Greist et al.
Arch Gen Psychiatry 1995;52:53-60.
ABSTRACT